NPHLA Daily
NPHLA Daily
Wednesday, November 11, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 5 trial updates, 1 new study
NPHLA tracked 6 new official records on this desk today: 5 trial updates, 1 new study. First: New trial registered: RESIST-MIND (Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss)
Metabolic signal
Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial
From Nature medicine.
Regulatory signal
What changed today in Regulatory: 1 recall record, 1 Federal Register notice
NPHLA tracked 2 new official records on this desk today: 1 recall record, 1 Federal Register notice. First: Recall: Family Farmstead Dairy Announces Recall of All Cheddar Cheese Products Because of Possible Health Risk — reason given: not stated (firm: not stated).
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 1 trial update, 1 recall record
NPHLA tracked 2 new official records on this desk today: 1 trial update, 1 recall record. First: Results posted on ClinicalTrials.gov: PAOLA (A Study of NT 201 Doses in the Treatment of Platysma Prominence)
AI & Technology signal
Artificial intelligence in healthcare: clinical applications, evidence maturity, risks, and life-cycle governance
From International journal of medical informatics.
One thing worth watching
Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…
November 26, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 5 trial updates, 1 new study
- What changed today in Regulatory: 1 recall record, 1 Federal Register notice
- What changed today in Aesthetics & Longevity: 1 trial update, 1 recall record
- Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial (Nature medicine)
- New trial registered: A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity (ClinicalTrials.gov (U.S. National Library of Medicine))
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.